Oncor preparing for clinical trials of p43 early-stage breast cancer test.
This article was originally published in The Gray Sheet
Executive Summary
ONCOR PMA FOR p43 EARLY-STAGE BREAST CANCER DETECTION TEST is slated for submission to FDA in 12-18 months, the company says. The premarket approval application likely will be supported by data from an upcoming four-center clinical trial. However, Oncor also is examining the possibility of a PMA based on retrospective data with prospective data gathered after approval. The company is working with FDA to design the four-site study, which will be led by researchers from the Albany Medical Center, New York.
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.